Deviance (sociology)

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Retrieved on: 
Thursday, March 14, 2024
Central nervous system, Patient, Hope, Soroka Medical Center, Clinical trial, Safety, Disorder, TEL, Deviance (sociology), ASD, Autism spectrum, Pharmaceutical industry

TEL AVIV, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center for pediatric patients who have Autism Spectrum Disorder ("ASD"). This significant milestone follows the Company's recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling the commencement of dosing.

Key Points: 
  • This significant milestone follows the Company's recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling the commencement of dosing.
  • "Dosing the first patient is always an exciting moment in any clinical trial.
  • We are grateful to the patients, Professor Meiri and his team involved in the clinical trial.
  • Designed as a randomized, double-blind, placebo-controlled clinical trial with cross-over, the study will span 20 weeks and enroll 60 children.

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

Retrieved on: 
Thursday, February 29, 2024
Central nervous system, Soroka Medical Center, TEL, Spectrum, ASD, Safety, Autism spectrum, Patient, Disorder, Clinical trial, Deviance (sociology), Pharmaceutical industry

TEL AVIV, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has successfully completed the manufacturing of and delivered its innovative SCI- 210 treatment, in accordance with its initiation of enrollment for the clinical trial at the Soroka Medical Center of pediatric patients who have Autism Spectrum Disorder ("ASD").

Key Points: 
  • "A clinical trial is a complicated project composed of many little steps- which in turn help ensure successful execution.
  • Having the clinical supply ready on site is the final step before first patient is administered treatment.
  • The clinical trial will rigorously examine the safety, tolerability, and efficacy of SCI- 210, in comparison to CBD monotherapy, for the treatment of ASD.
  • Designed as a randomized, double-blind, placebo-controlled clinical trial with cross-over, the clinical trial will span 20 weeks and enroll 60 children.

SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

Retrieved on: 
Monday, January 29, 2024
ASD, Spectrum, Health, Soroka Medical Center, Social, Cannabidiol, Communication, Deviance (sociology), TEL, CBD, Central nervous system, Clinical trial, Behavior, Trial of the century

TEL AVIV, Israel, Jan. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announces the initiation of patient recruitment for its clinical trial in children suffering from autism spectrum disorder ("ASD") at Soroka Medical Center in Israel.

Key Points: 
  • The Company's goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
  • “We hope the outcome of the trial will enable the Company to procced with the commercialization process for SCI-210 in Israel."
  • The trial was designed in consultation with the National Autism Research Center, the leading research center for autism in Israel.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

Retrieved on: 
Friday, September 29, 2023
DSM-IV codes, Central nervous system, Social, Autism spectrum, Clinical trial, Quality of life, Clinical Global Impression, Disorder, TEL, PEA, Patient safety, ASD, Deviance (sociology), Neurology, Cannabidiol, Safety, Pharmaceutical industry, CBD

Designed as a randomized, double-blind, placebo-controlled trial with a cross-over study, the trial will span 20 weeks and involve 60 children between 5-18 years old.

Key Points: 
  • Designed as a randomized, double-blind, placebo-controlled trial with a cross-over study, the trial will span 20 weeks and involve 60 children between 5-18 years old.
  • Partnering with the National Autism Research Center, Israel's foremost authority on autism research, underscores our unwavering commitment to scientific rigor and patient safety.
  • The trial was designed in collaboration with the National Autism Research Center, Israel's leading institution for autism research.
  • The term "spectrum" in Autism Spectrum Disorder encapsulates the wide array of symptoms and severity levels associated with this complex condition.

Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen

Retrieved on: 
Monday, September 18, 2023
Social Responsiveness Scale, Autism spectrum, Allos, DSM-IV codes, Social domain, Fragile X syndrome, Patent, Patient, Deviance (sociology), Orphan, FDA, International Society, Pharmaceutical industry, EU, MD

CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has expanded its intellectual property rights with a new patent family.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has expanded its intellectual property rights with a new patent family.
  • Expanded arbaclofen rights with a newly filed patent family and with exclusive rights in all indications, incl.
  • Allos also announces today the worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, including Autism Spectrum Disorder.
  • Dr. Randall Carpenter, MD, co-founder of Allos Pharma Inc

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

Retrieved on: 
Friday, July 14, 2023
Communication, Ministry of Health (Israel), Status epilepticus, Central nervous system, Social, Spectrum, Professional, Clinical trial, Tourette syndrome, Clinical Global Impression, IMCA, Agitation, Sale, Pain, Ministry, TEL, Behavior, ASD, Deviance (sociology), Cannabis, THC, Alzheimer's disease, Cannabidiol, Safety, Pharmaceutical industry, Vaccine, Health, CBD

TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder ("ASD"). SCI-210 is a proprietary combination of cannabidiol (“CBD”) and CannAmide™.

Key Points: 
  • "The initiation of this clinical trial represents a significant step forward for our proprietary SCI-210 as we work to develop a novel treatment for children and adolescents with ASD.
  • The design of the study includes a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children.
  • The trial was designed in consultation with the National Autism Research Center, the leading research center for autism in Israel.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders

Retrieved on: 
Wednesday, July 5, 2023
Epilepsy, Obesity, Therapy, Social Responsiveness Scale, Schizophrenia, Autism spectrum, Public, Parent, Vineland, Clinical trial, Clinical research associate, DSM-IV codes, Patient, ASD, Child, ABC, Spectrum, CBD, OTC, Deviance (sociology), Alzheimer's disease, Safety, Pharmaceutical industry, Health

The Company previously announced that it is planning to conduct a Phase II clinical trial spearheaded by principal investigator, Dr. Adi Aran, M.D., to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric disorders such as Parkinson’s Disease, Alzheimer’s Disease, schizophrenia, and epilepsy.

Key Points: 
  • The Company previously announced that it is planning to conduct a Phase II clinical trial spearheaded by principal investigator, Dr. Adi Aran, M.D., to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric disorders such as Parkinson’s Disease, Alzheimer’s Disease, schizophrenia, and epilepsy.
  • The patients will be randomized in a 1:1 ratio to receive either GCANRx’s therapeutic or a matched placebo.
  • “We are excited to announce that GCANRx has received a final official approval to embark on its Phase II Clinical Trial for our therapeutic aimed at treating ASD and other neuropsychiatric disorders.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder

Retrieved on: 
Monday, February 27, 2023
Olam, Clinical trial, Safety, Central nervous system, Social, Ministry, Soroka, Deviance (sociology), Spectrum, Trial, ASD, Behavior, TEL, Cannabidiol, TASE, Ethics committee, Communication, Clinical Global Impression, Pharmaceutical industry, Vaccine, Health, CBD

 TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of  the central nervous system, today announced it has signed an agreement with Israel's leading and pioneer manufacturer and distributer of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE: TKUN), to supply CBD-rich oil from Cannbit strains by, to be used as part of its proprietary SCI-210 treatment, which is a combination of CBD and CannAmide™. SCI-210 treatment will be used in the Company's clinical trial ("Trial") on children with autism spectrum disorder (“ASD”).

Key Points: 
  • SCI-210 treatment will be used in the Company's clinical trial ("Trial") on children with autism spectrum disorder (“ASD”).
  • The Trial will be conducted at the Soroka University Medical Center, led by Prof. Gal Meiri, head of the Soroka Preschool Psychiatry Unit.
  • "We are nearing the end of our preparations to begin our clinical trial on children with autism spectrum disorder.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

Retrieved on: 
Wednesday, January 18, 2023
Soroka Medical Center, Autism, Communication, Clinical Global Impression, Trial of the century, Cannabidiol, Safety, Ministry, Ethics committee, Central nervous system, Patient, Deviance (sociology), Behavior, ASD, Binary relation, TEL, Pharmaceutical industry, CBD, Health

TEL AVIV, Israel, Jan. 18, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval by the Soroka University Medical Center (“Soroka Medical Center”) to conduct its clinical study for SCI-210 in patients suffering from autism spectrum disorder ("ASD").

Key Points: 
  • On January 9, 2023, SciSparc announced it signed an agreement with Soroka Medical Center to perform its clinical study, led by Prof. Gal Meiri, head of Soroka Medical Center’s Preschool Psychiatry Unit.
  • During 2022, the Company received approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka Medical Center to conduct the Company’s clinical trial.
  • The design of the study includes a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center

Retrieved on: 
Monday, January 9, 2023
Autism, Communication, Clinical Global Impression, Cannabidiol, Safety, Ministry, Research, Tourette syndrome, Ethics committee, Agitation, Central nervous system, Diagnosis, Patient, Deviance (sociology), Behavior, Clinical trial, Soroka Medical Center, Alzheimer's disease, IIB, IIA, ASD, Binary relation, TEL, Pharmaceutical industry, CBD, Health

TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed an agreement with the Soroka University Medical Center, in Be'er-Sheva, Israel ("Soroka Medical Center") to conduct the Company’s clinical study for SCI-210 in patients suffering from autism spectrum disorder ("ASD").

Key Points: 
  • During 2022, the Company received approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Company’s clinical trial.
  • “The signing of the agreement with Soroka Medical Center represents another step towards commencing our clinical trial in ASD,” commented Oz Adler, SciSparc's Chief Executive Officer.
  • Soroka Medical Center is yet another example for our continuous efforts to collaborate with leading medical institutions in the world."
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.